JP2006523695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523695A5 JP2006523695A5 JP2006509780A JP2006509780A JP2006523695A5 JP 2006523695 A5 JP2006523695 A5 JP 2006523695A5 JP 2006509780 A JP2006509780 A JP 2006509780A JP 2006509780 A JP2006509780 A JP 2006509780A JP 2006523695 A5 JP2006523695 A5 JP 2006523695A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amount
- solution
- aminoglycoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 69
- 238000000034 method Methods 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 22
- 239000000243 solution Substances 0.000 claims 22
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 19
- 229940126575 aminoglycoside Drugs 0.000 claims 19
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims 16
- 229960003865 tazobactam Drugs 0.000 claims 16
- 229960002292 piperacillin Drugs 0.000 claims 15
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 15
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 13
- 239000002738 chelating agent Substances 0.000 claims 13
- 229960004821 amikacin Drugs 0.000 claims 10
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 10
- 238000007911 parenteral administration Methods 0.000 claims 10
- 239000000872 buffer Substances 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 238000001990 intravenous administration Methods 0.000 claims 6
- 208000035143 Bacterial infection Diseases 0.000 claims 5
- 239000003125 aqueous solvent Substances 0.000 claims 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229960000707 tobramycin Drugs 0.000 claims 5
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960001484 edetic acid Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229960003330 pentetic acid Drugs 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 4
- 239000001509 sodium citrate Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008121 dextrose Substances 0.000 claims 3
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 3
- 239000008215 water for injection Substances 0.000 claims 3
- FCKYPQBAHLOOJQ-NXEZZACHSA-N 2-[[(1r,2r)-2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)[C@@H]1CCCC[C@H]1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-NXEZZACHSA-N 0.000 claims 2
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 2
- IWBOPFCKHIJFMS-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl) ether Chemical compound NCCOCCOCCN IWBOPFCKHIJFMS-UHFFFAOYSA-N 0.000 claims 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000007872 degassing Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 229960005264 piperacillin sodium Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229960000373 tazobactam sodium Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46280803P | 2003-04-14 | 2003-04-14 | |
| PCT/US2004/010698 WO2004091666A1 (en) | 2003-04-14 | 2004-04-07 | Compositions containing piperacillin and tazobactam useful for injection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006523695A JP2006523695A (ja) | 2006-10-19 |
| JP2006523695A5 true JP2006523695A5 (https=) | 2007-06-07 |
| JP4644659B2 JP4644659B2 (ja) | 2011-03-02 |
Family
ID=32326726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509780A Expired - Lifetime JP4644659B2 (ja) | 2003-04-14 | 2004-04-07 | 注射に有用なピペラシリンおよびタゾバクタムを含有する組成物 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7498312B2 (https=) |
| EP (1) | EP1468697B1 (https=) |
| JP (1) | JP4644659B2 (https=) |
| KR (1) | KR100824554B1 (https=) |
| CN (1) | CN1802179B (https=) |
| AR (1) | AR043863A1 (https=) |
| AT (1) | ATE381947T1 (https=) |
| AU (1) | AU2004229407B2 (https=) |
| BR (1) | BRPI0409450B8 (https=) |
| CA (1) | CA2464258C (https=) |
| CH (1) | CH695185A9 (https=) |
| CL (1) | CL2004000782A1 (https=) |
| CO (1) | CO5700796A2 (https=) |
| CR (2) | CR8035A (https=) |
| CY (1) | CY1108064T1 (https=) |
| DE (1) | DE602004010862T2 (https=) |
| DK (1) | DK1468697T3 (https=) |
| EC (1) | ECSP056100A (https=) |
| ES (1) | ES2298672T3 (https=) |
| FR (1) | FR2853547B1 (https=) |
| GB (1) | GB2400557B (https=) |
| IL (1) | IL171337A (https=) |
| MX (1) | MXPA05010996A (https=) |
| MY (1) | MY139099A (https=) |
| NO (1) | NO20054789L (https=) |
| NZ (1) | NZ543005A (https=) |
| PL (1) | PL1468697T3 (https=) |
| PT (1) | PT1468697E (https=) |
| RU (2) | RU2322980C2 (https=) |
| SA (1) | SA04250119B1 (https=) |
| SI (1) | SI1468697T1 (https=) |
| TW (1) | TWI308069B (https=) |
| WO (1) | WO2004091666A1 (https=) |
| ZA (1) | ZA200508315B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110209B2 (en) | 2002-12-20 | 2012-02-07 | Xeris Pharmaceuticals Inc. | Intracutaneous injection |
| EP1468697B1 (en) * | 2003-04-14 | 2007-12-26 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
| KR20070110256A (ko) * | 2004-10-14 | 2007-11-16 | 와이어쓰 | 유산나트륨 희석제 내에 피페라실린, 타조박탐 및아미노카르복실산을 함유하는 조성물 |
| PT1841432E (pt) * | 2004-12-02 | 2010-10-25 | Venus Remedies Ltd | Composições para combater a resistência aos antibióticos mediada pela beta-lactamase usando inibidores da betalactamase úteis para injecção |
| ES2284318B1 (es) * | 2005-04-13 | 2008-11-01 | Labiana Development, S.L. | Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable. |
| ITMI20051630A1 (it) | 2005-09-02 | 2007-03-03 | Acs Dobfar Spa | Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| CN102210679B (zh) * | 2006-08-25 | 2013-03-13 | 天津和美生物技术有限公司 | 含哌拉西林的抗生素复方 |
| CN102441169A (zh) * | 2006-08-25 | 2012-05-09 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| CN1927201B (zh) * | 2006-08-25 | 2011-06-01 | 天津和美生物技术有限公司 | 含哌拉西林的抗生素复方 |
| CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
| CN101265263B (zh) * | 2008-05-12 | 2010-06-02 | 海南百那医药发展有限公司 | 哌拉西林钠他唑巴坦钠复方注射剂的生产方法 |
| JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
| JP5852316B2 (ja) * | 2010-03-30 | 2016-02-03 | 富山化学工業株式会社 | ピペラシリン含有懸濁液の製造法 |
| WO2012012460A1 (en) | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
| BR112013012735B1 (pt) | 2010-11-25 | 2021-11-23 | Allecra Therapeutics Gmbh | Composição farmacêutica inibidora de ss-lactamase |
| EP2683364B1 (en) | 2011-03-10 | 2017-01-18 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
| WO2013067022A1 (en) | 2011-10-31 | 2013-05-10 | Xeris Pharmaceuticals, Inc. | Formulations for the treatment of diabetes |
| EP3431092A1 (en) | 2012-03-26 | 2019-01-23 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| US8476425B1 (en) * | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
| KR101816798B1 (ko) * | 2012-10-19 | 2018-01-10 | 주식회사유한양행 | 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물 |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| US9320740B2 (en) | 2013-03-15 | 2016-04-26 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
| CN110279698B (zh) | 2013-03-15 | 2022-10-28 | 默沙东有限责任公司 | 头孢特咯瓒抗生素组合物 |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| EP3043797B1 (en) | 2013-09-09 | 2020-04-08 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| US20150094293A1 (en) | 2013-09-27 | 2015-04-02 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| EP3185932A1 (en) | 2014-08-06 | 2017-07-05 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
| KR20170067709A (ko) * | 2014-10-08 | 2017-06-16 | 사와이세이야쿠 가부시키가이샤 | 동결 건조 제제의 제조 방법 |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
| AU2017242135A1 (en) * | 2016-03-31 | 2017-11-02 | Wockhardt Limited | Antibacterial compositions |
| WO2018025248A1 (en) * | 2016-08-05 | 2018-02-08 | Jodas Expoim Private Limited | Edta injection and process for making the same |
| US11020403B2 (en) | 2017-06-02 | 2021-06-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| US11110054B2 (en) * | 2018-05-09 | 2021-09-07 | Slayback Pharma Llc | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
| CN112618486B (zh) * | 2020-12-24 | 2023-07-18 | 浙江昂利康制药股份有限公司 | 一种注射用混悬油剂及其制备方法 |
| CN113209030B (zh) * | 2021-04-27 | 2023-04-25 | 海南通用康力制药有限公司 | 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法 |
| WO2025253343A1 (en) * | 2024-06-06 | 2025-12-11 | Chandan Chopra | AN ANTIBIOTIC COMPOSITION OF A PENICILLIN, A β-LACTAMASE INHIBITOR AND AN ION-CHELATING AGENT |
| CN119367287B (zh) * | 2024-12-27 | 2025-03-28 | 成都硕德药业有限公司 | 一种重酒石酸去甲肾上腺素注射液及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4477452A (en) | 1981-03-26 | 1984-10-16 | American Cyanamid Company | Composition of matter comprising a lyophilized preparation of a penicillin derivative |
| US4534977A (en) | 1981-03-26 | 1985-08-13 | American Cyanamid Company | Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin |
| US4562073A (en) | 1982-12-24 | 1985-12-31 | Taiho Pharmaceutical Company Limited | Penicillin derivatives |
| US5763480A (en) * | 1994-02-14 | 1998-06-09 | The Jewish Hospital Of St. Louis | Inhibitors of cell-medicated disorders |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6207661B1 (en) * | 1999-02-22 | 2001-03-27 | Baxter International Inc. | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
| EP1499341A4 (en) * | 2002-04-18 | 2010-10-27 | Univ Iowa Res Found | METHOD FOR INHIBITING AND TREATING BACTERIAL BIOFILMS WITH METAL CHELATE IMAGES |
| EP1468697B1 (en) * | 2003-04-14 | 2007-12-26 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
| WO2004098643A1 (en) * | 2003-04-14 | 2004-11-18 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
| US6900184B2 (en) | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
-
2004
- 2004-04-06 EP EP04076075A patent/EP1468697B1/en not_active Expired - Lifetime
- 2004-04-06 ES ES04076075T patent/ES2298672T3/es not_active Expired - Lifetime
- 2004-04-06 PL PL04076075T patent/PL1468697T3/pl unknown
- 2004-04-06 CN CN2004800159296A patent/CN1802179B/zh not_active Ceased
- 2004-04-06 AT AT04076075T patent/ATE381947T1/de active
- 2004-04-06 RU RU2005135135/15A patent/RU2322980C2/ru active
- 2004-04-06 DK DK04076075T patent/DK1468697T3/da active
- 2004-04-06 PT PT04076075T patent/PT1468697E/pt unknown
- 2004-04-06 SI SI200430609T patent/SI1468697T1/sl unknown
- 2004-04-06 DE DE602004010862T patent/DE602004010862T2/de not_active Expired - Lifetime
- 2004-04-07 GB GB0407853A patent/GB2400557B/en not_active Expired - Fee Related
- 2004-04-07 WO PCT/US2004/010698 patent/WO2004091666A1/en not_active Ceased
- 2004-04-07 KR KR1020057019689A patent/KR100824554B1/ko not_active Expired - Lifetime
- 2004-04-07 BR BRPI0409450A patent/BRPI0409450B8/pt not_active IP Right Cessation
- 2004-04-07 TW TW093109588A patent/TWI308069B/zh not_active IP Right Cessation
- 2004-04-07 NZ NZ543005A patent/NZ543005A/en not_active IP Right Cessation
- 2004-04-07 JP JP2006509780A patent/JP4644659B2/ja not_active Expired - Lifetime
- 2004-04-07 US US10/553,139 patent/US7498312B2/en not_active Expired - Lifetime
- 2004-04-07 MX MXPA05010996A patent/MXPA05010996A/es active IP Right Grant
- 2004-04-07 AU AU2004229407A patent/AU2004229407B2/en not_active Expired
- 2004-04-08 CA CA002464258A patent/CA2464258C/en not_active Expired - Lifetime
- 2004-04-09 MY MYPI20041292A patent/MY139099A/en unknown
- 2004-04-09 FR FR0403786A patent/FR2853547B1/fr not_active Expired - Fee Related
- 2004-04-12 CL CL200400782A patent/CL2004000782A1/es unknown
- 2004-04-13 CH CH00641/04A patent/CH695185A9/fr not_active IP Right Cessation
- 2004-04-13 AR ARP040101237A patent/AR043863A1/es active IP Right Grant
- 2004-05-18 SA SA4250119A patent/SA04250119B1/ar unknown
-
2005
- 2005-10-07 CR CR8035A patent/CR8035A/es unknown
- 2005-10-10 IL IL171337A patent/IL171337A/en active IP Right Grant
- 2005-10-13 ZA ZA200508315A patent/ZA200508315B/en unknown
- 2005-10-14 EC EC2005006100A patent/ECSP056100A/es unknown
- 2005-10-18 NO NO20054789A patent/NO20054789L/no not_active Application Discontinuation
- 2005-11-09 CO CO05114116A patent/CO5700796A2/es not_active Application Discontinuation
-
2007
- 2007-11-16 RU RU2007142454/15A patent/RU2007142454A/ru not_active Application Discontinuation
-
2008
- 2008-03-04 CR CR9792A patent/CR9792A/es not_active Application Discontinuation
- 2008-03-06 CY CY20081100258T patent/CY1108064T1/el unknown
-
2009
- 2009-02-13 US US12/370,794 patent/US7915229B2/en not_active Expired - Lifetime
-
2011
- 2011-02-24 US US13/033,861 patent/US8133883B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523695A5 (https=) | ||
| RU2005135135A (ru) | Композиции, содержащие пиперациллин и тазобактам, применимые для инъекции | |
| JP2013540104A (ja) | 延長された保存安定性を有するペメトレキセドを含有する医薬組成物 | |
| JP2011502968A5 (https=) | ||
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| CN115990138A (zh) | 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法 | |
| BRPI0719096A2 (pt) | Formulação parenteral estavel contendo uminibidor de rsv de uma estrutura de benzodiazepina | |
| JP2011137048A (ja) | 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス | |
| JP5070670B2 (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤およびその製造方法 | |
| CN101433519B (zh) | 阿奇霉素滴眼剂及其制备方法 | |
| TWI860656B (zh) | 包含異唑啉衍生物之注射用製劑及其製造方法 | |
| TWI343261B (en) | Injectable dosage form of flupirtine | |
| CN102123714A (zh) | 莰佛胺制剂及其制备 | |
| JP2005528351A5 (https=) | ||
| RU2423130C2 (ru) | Композиция, содержащая эпопростенол, и способ ее получения | |
| CN118574603A (zh) | 包含异𫫇唑啉衍生物的注射制剂及其制备方法 | |
| CN101422438A (zh) | 一种不含辅料的复方二氯醋酸二异丙胺冻干制剂及制备工艺 | |
| JP2026016486A5 (https=) | ||
| JP2005200409A (ja) | 注射剤 | |
| CO6270207A2 (es) | Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]metil]fenil-2e-2-propenamida y procedimientos para su preparacion | |
| CN103037848A (zh) | 氟吡汀的可注射剂型 | |
| CN1615845A (zh) | 单位剂量形式的去甲基斑蝥酸或其衍生物粉针制剂及其制备方法 | |
| HK40025124A (en) | Composition for injection | |
| HK1091146B (en) | New use, pharmaceutical preparations as well as a process for their production | |
| CN103083253A (zh) | 对乙酰氨基酚冻干制剂及其制备方法 |